11.07.2015 Views

Prescribed Drugs Provider Manual - Iowa Department of Human ...

Prescribed Drugs Provider Manual - Iowa Department of Human ...

Prescribed Drugs Provider Manual - Iowa Department of Human ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

<strong>Iowa</strong><strong>Department</strong><strong>of</strong> <strong>Human</strong>Services<strong>Provider</strong> and Chapter<strong>Prescribed</strong> <strong>Drugs</strong>Page3DateAugust 1, 2013Page47. Linezolid (Zyvox ® ) ............................................................................. 4948. Mifepristone (Korlym ® )....................................................................... 5049. Modified Formulations ........................................................................ 5050. Muscle Relaxants ............................................................................... 5151. Narcotic Agonist-Antagonist Nasal Sprays .............................................. 5152. Nebivolol (Bystolic ® ) .......................................................................... 5253. Nicotine Replacement Products ............................................................ 5254. Nonparenteral Vasopressin Derivatives <strong>of</strong> Posterior Pituitary HormoneProducts ........................................................................................... 5355. Nonpreferred <strong>Drugs</strong> ........................................................................... 5456. Nonsteroidal Anti-Inflammatory <strong>Drugs</strong> .................................................. 5457. Omalizumab (Xolair ® ) ........................................................................ 5558. Oxycodone ER/CR (OxyContin ® ) .......................................................... 5659. Palivizumab (Synagis ® ) ...................................................................... 5660. Proton Pump Inhibitors ....................................................................... 5861. Pulmonary Arterial Hypertension Agents ................................................ 5962. Quantity Limit Override ...................................................................... 60a. Initial 15-Day Limit ..................................................................... 60b. Monthly Limits ............................................................................ 6063. R<strong>of</strong>lumilast (Daliresp) ...................................................................... 8164. Sedative/Hypnotics-Non-Benzodiazepine ............................................... 8265. Selected Brand-Name <strong>Drugs</strong> ................................................................ 8266. Serotonin 5-HT1 Receptor Agonists ...................................................... 8367. Short-Acting Narcotics ........................................................................ 8468. Smoking Cessation Therapy-Oral ......................................................... 8469. Sodium Oxybate (Xyrem ® ).................................................................. 8570. Thrombopoietin Receptor Agonists ....................................................... 8571. Topical Retinoids ............................................................................... 8672. Vemurafenib (Zelboraf).................................................................... 8773. Vilazodone (Viibryd ) ......................................................................... 8774. Vitamins, Minerals and Multiple Vitamins ............................................... 8875. Vusion Ointment ............................................................................. 88D. BASIS OF PAYMENT FOR DRUGS AND SUPPLIES ............................................ 891. Reimbursement Effective February 1, 2013 ........................................... 90a. Generic and Nonprescription <strong>Drugs</strong> ............................................... 90b. Brand-Name <strong>Drugs</strong> ..................................................................... 902. <strong>Drugs</strong> Subject to Federal Upper Limit (FUL) ........................................... 90a. FUL Development ....................................................................... 90b. Reimbursement for FUL <strong>Drugs</strong> ...................................................... 913. Reimbursement for Unit-Dose Packaging ............................................... 914. Reimbursement for Vaccinations .......................................................... 92

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!